Summary & Overview
HCPCS S3854: Gene Expression Profiling Panel for Breast Cancer
HCPCS Level II code S3854 denotes a gene expression profiling panel used to guide management of breast cancer treatment. As a molecular diagnostic test, it evaluates tumor gene expression patterns to assist clinicians and oncology teams in selecting systemic therapies and estimating prognosis, making it an important tool in personalized oncology care nationwide. Coverage and use of such assays influence treatment planning, utilization of targeted therapies, and care pathways across payers.
Key payers considered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for gene expression profiling in breast cancer, typical sites of service, and the types of benchmarks and policy dimensions commonly examined for this code: payer coverage trends, Medicare policy alignment, and implications for laboratory billing and prior authorization workflows. The publication also summarizes common modifiers associated with laboratory and diagnostic services and notes when additional coding detail is required.
The content is intended for national audiences including billing teams, laboratory directors, oncology care managers, and policy analysts who need a clear summary of what S3854 represents, which payers commonly interact with this service, and what topics to review when assessing coverage or operational impacts for gene expression assays in breast cancer management.
Billing Code Overview
HCPCS Level II code S3854 represents a gene expression profiling panel for use in the management of breast cancer treatment. This service involves laboratory testing that analyzes the expression of multiple genes in a tumor sample to inform therapeutic decision-making for patients with breast cancer.
-
Service type: Molecular diagnostic / gene expression profiling
-
Typical site of service: Clinical laboratory or outpatient pathology/molecular diagnostics setting
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 52-year-old woman with newly diagnosed, early-stage, hormone receptor–positive, HER2-negative invasive breast carcinoma undergoes surgical lumpectomy. Final pathology reports a 1.8 cm tumor, grade 2, with 0/3 sentinel lymph nodes involved. The multidisciplinary breast oncology team considers adjuvant chemotherapy versus endocrine therapy alone. The treating medical oncologist orders a gene expression profiling panel (S3854) on the resected tumor specimen to estimate recurrence risk and potential chemotherapy benefit.
Specimen handling and workflow: the surgical pathology laboratory prepares a formalin-fixed paraffin-embedded tumor block and sends the requested block or extracted RNA to the clinical laboratory that performs the gene expression test. The ordering clinician documents clinical indication, tumor characteristics (size, grade, node status, ER/PR/HER2 status), and a signed consent if required by the testing laboratory. Results are returned to the oncologist and reviewed at a tumor board or clinic visit to guide adjuvant therapy selection and shared decision-making with the patient.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard pricing or no modifier applicable | Rarely appended; indicates normal service when no other modifier applies |
| Unusual procedural services — increased procedural services | Use if the test required substantially greater work or documentation beyond typical processing (rare for standardized panels)